2008
DOI: 10.1016/j.ijrobp.2008.06.1180
|View full text |Cite
|
Sign up to set email alerts
|

ERCC1, COX-2, and p53 Expression in Patients with Locally Advanced Cervical Cancer Treated with Chemoradiotherapy and Celecoxib: A Quantitative Immunohistochemical Analysis of RTOG 0128

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2015
2015
2015
2015

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…Therefore, Cox-2 specific inhibitors have been developed to target on malignant tissue growth and have achieved clinical benefit, although the cardiovascular side-effects associated with their use have greatly hampered their popularity (Doll et al, 2012;Ho et al, 2012;Katkoori et al, 2012). However, the definitive chemopreventive benefit derived from use of Cox-2 specific inhibitors confirms that prostaglandin pathway can serve as a valid target for chemoprevention.…”
Section: Introductionmentioning
confidence: 99%
“…Therefore, Cox-2 specific inhibitors have been developed to target on malignant tissue growth and have achieved clinical benefit, although the cardiovascular side-effects associated with their use have greatly hampered their popularity (Doll et al, 2012;Ho et al, 2012;Katkoori et al, 2012). However, the definitive chemopreventive benefit derived from use of Cox-2 specific inhibitors confirms that prostaglandin pathway can serve as a valid target for chemoprevention.…”
Section: Introductionmentioning
confidence: 99%